Global EditionThursday, 28 May 2026 at 09:21 pmLive Desk OpenPremium world briefings with timeline, impact, and future-watch analysis.
AtlasHourPremium world newspaper
Search
Health & Science

Synklino announces first patient dosed in Phase 1 trial of SYN002 for CMV prevention in kidney transplantation

Study to evaluate the safety and exploratory efficacy of SYN002 in recipients of human cytomegalovirus (CMV) positive donor kidneys, and to monitor for viral reactivation over the six months following transplantation Investigator-sponsored Phase 1 trial underway at the Ajmera Transplant Centre, University Health Network (UHN), Toronto, a world-renowned transplant center, conducted by Professor Atul HumarBuilds on preclinical human kidney proof-of-concept data published in the American Journal of Transplantation demonstrating that SYN002 is associated with >90% reduction in CMV reactivation from latency COPENHAGEN, Denmark, May 28, 2026 (GLOBE NEWSWIRE) -- Synklino A/S, a clinical-stage biotechnology company developing a first-in-class, ex vivo therapy to transform kidney transplantation outcomes through better CMV prevention, today announces the first patient has been dosed in a first-in-human Phase 1 clinical trial of SYN002 for the prevention of cytomegalovirus (CMV) reactivation in kidney transplant recipients.

By The Manila TimesPublished 28 May, 07:44 amUpdated 28 May, 07:44 am3 min read
Verified ContextSource-linkedAtlasHour DeskUpdated28 May, 07:44 amAI summary checked for clarity

What happened

Study to evaluate the safety and exploratory efficacy of SYN002 in recipients of human cytomegalovirus (CMV) positive donor kidneys, and to monitor for viral reactivation over the six months following transplantation Investigator-sponsored Phase 1 trial underway at the Ajmera Transplant Centre, University Health Network (UHN), Toronto, a world-renowned transplant center, conducted by Professor Atul HumarBuilds on preclinical human kidney proof-of-concept data published in the American Journal of Transplantation demonstrating that SYN002 is associated with >90% reduction in CMV reactivation from latency COPENHAGEN, Denmark, May 28, 2026 (GLOBE NEWSWIRE) -- Synklino A/S, a clinical-stage biotechnology company developing a first-in-class, ex vivo therapy to transform kidney transplantation outcomes through better CMV prevention, today announces the first patient has been dosed in a first-in-human Phase 1 clinical trial of SYN002 for the prevention of cytomegalovirus (CMV) reactivation in kidney transplant recipients.

Why it matters

AtlasHour context: this story may affect public policy, global affairs, business confidence, technology direction, energy security, or civic life.

Global context

The story is being tracked through Global Markets.

Who is affected

Global Markets are the visible context tags. AtlasHour frames them as audience, sector, and public-interest signals for editorial context.

What to watch next

Readers should watch official responses, local reaction, source updates, and whether the story changes the next decision cycle.

Read the original source
Why It Matters

The consequence layer

AtlasHour context: this story may affect public policy, global affairs, business confidence, technology direction, energy security, or civic life.

Watch Next

What To Watch Next

Next event: official statement, institutional response, or source update.

Public reaction: watch regional response and whether this story widens beyond the first report.

Next update window: the next 24 hours, or sooner if verified information changes.

Key Facts

Three facts to keep in view

1Source

The Manila Times

3 min readRead time

Designed for a concise world-news brief.

1Context tags

Used for editorial story mapping and source context.

Read Next

Related Stories

Health & Science28 May, 07:44 am

ViCentra Scales Commercial Manufacturing, Triples Capacity and Strengthens Unit Economics

Commercial-scale production of Kaleido consumables begins at contract manufacturer Phillips MedisizeManufacturing capacity more than triples, with initial capacity to support over 17,000 usersVolume manufacturing drives gross margin expansion UTRECHT, The Netherlands, May 28, 2026 (GLOBE NEWSWIRE) -- ViCentra, a European medical device company commercializing the Kaleido insulin patch pump system, today announced that commercial‑scale production of Kaleido consumables, including infusion sets and insulin cartridges, has begun at Phillips Medisize, a Molex company and leading global medical technology contract development and manufacturing organization (CDMO). The collaboration more than triples Kaleido consumables production capacity, with initial scale to support over 17,000 users. This expanded supply positions ViCentra to add thousands of new users across Germany, the Netherlands and France through the second half of 2026, with Germany representing the world’s second‑largest insulin pump market.

The Manila Times
Read Next

More From This Section

AtlasHour updates articles as new verified information becomes available. Corrections and source context can be sent to the newsroom.